Optimizing polytherapy management for Dravet syndrome in the United States: A National Expert Consensus Authors: Elaine Wirrell, Joseph Sullivan Published: 2026 Key points Dravet syndrome is a severe, drug‐resistant developmental and epileptic encephalopathy that requires complex, long‐term polytherapy.Optimizing treatment combinations in DS requires clinicians to carefully balance multiple factors, underscoring the need for a comprehensive and holistic management approach.This US‐focused consensus integrates published evidence and real‐world clinical expertise to define practical principles for optimizing polytherapy management in Dravet syndrome. Key points Dravet syndrome is a severe, drug‐resistant developmental and epileptic encephalopathy that requires complex, long‐term polytherapy.Optimizing treatment combinations in DS requires clinicians to carefully balance multiple factors, underscoring the need for a comprehensive and holistic management approach.This US‐focused consensus integrates published evidence and real‐world clinical expertise to define practical principles for optimizing polytherapy management in Dravet syndrome. Dravet syndrome is a severe, drug‐resistant developmental and epileptic encephalopathy that requires complex, long‐term polytherapy. Dravet syndrome is a severe, drug‐resistant developmental and epileptic encephalopathy that requires complex, long‐term polytherapy. Optimizing treatment combinations in DS requires clinicians to carefully balance multiple factors, underscoring the need for a comprehensive and holistic management approach. Optimizing treatment combinations in DS requires clinicians to carefully balance multiple factors, underscoring the need for a comprehensive and holistic management approach. This US‐focused consensus integrates published evidence and real‐world clinical expertise to define practical principles for optimizing polytherapy management in Dravet syndrome. This US‐focused consensus integrates published evidence and real‐world clinical expertise to define practical principles for optimizing polytherapy management in Dravet syndrome. INTRODUCTION Dravet syndrome (DS) is a severe, drug‐resistant developmental and epileptic encephalopathy (DEE) that manifests between 1 and 20 months of age, in previously healthy infants, presenting with a range of initial seizure types, often including prolonged bilateral tonic–clonic seizures. As the disorder progresses, additional seizure types including myoclonic, atypical absence, and focal seizures emerge, reflecting the evolving epileptic phenotype. Over time, affected individuals frequently develop cognitive impairment, behavioral and sleep disturbances, and motor dysfunction, leading to a complex, heterogeneous clinical presentation that profoundly affects the quality of life of both patients and their caregivers. 1 , 2 , 3 , 4 , 5 Management of patients with DS often requires the use of multiple antiseizure medications (ASMs) to achieve adequate seizure control, as first‐line agents such as valproate (VPA) and/or clobazam (CLB) alone are frequently insufficient. 6 , 7 Three DS‐specific agents have demonstrated efficacy in randomized controlled trials: 8 Stiripentol (STP), approved in Europe in 2007 for use with VPA and CLB without age restriction and approved in the United States (US) in 2018 for use with CLB, with a label expansion in 2022 to include children aged ≥ 6 months; 9 , 10 Cannabidiol (CBD), approved in the US in 2018, with a label expansion in 2020 to include children aged ≥ 1 year, and in Europe in 2019 (in combination with CLB) for patients aged ≥ 2 years; 11 Fenfluramine (FFA), authorized in both Europe and the US in 2020 for patients aged ≥ 2 years. 12 Stiripentol (STP), approved in Europe in 2007 for use with VPA and CLB without age restriction and approved in the United States (US) in 2018 for use with CLB, with a label expansion in 2022 to include children aged ≥ 6 months; 9 , 10 Stiripentol (STP), approved in Europe in 2007 for use with VPA and CLB without age restriction and approved in the United States (US) in 2018 for use with CLB, with a label expansion in 2022 to include children aged ≥ 6 months; 9 , 10 Cannabidiol (CBD), approved in the US in 2018, with a label expansion in 2020 to include children aged ≥ 1 year, and in Europe in 2019 (in combination with CLB) for patients aged ≥ 2 years; 11 Cannabidiol (CBD), approved in the US in 2018, with a label expansion in 2020 to include children aged ≥ 1 year, and in Europe in 2019 (in combination with CLB) for patients aged ≥ 2 years; 11 Fenfluramine (FFA), authorized in both Europe and the US in 2020 for patients aged ≥ 2 years. 12 Fenfluramine (FFA), authorized in both Europe and the US in 2020 for patients aged ≥ 2 years. 12 Other non–DS‐specific ASMs such as topiramate, levetiracetam, or bromides may be considered in selected cases despite limited evidence of efficacy in DS. 8 Additionally, ongoing clinical trials are investigating new, emerging therapies specifically for DS, with the aim to further improve treatment outcomes. 13 Overall, the increasing number of therapeutic options, together with the wide variability in seizure presentations, the frequent need for combination therapy, and the substantial burden of comorbidities, results in a particularly challenging treatment environment for clinicians. Despite the availability of multiple ASMs, many patients continue to experience suboptimal seizure control, an established hallmark of the multidrug‐resistant nature of DS. 7 This ongoing seizure burden frequently leads clinicians, in collaboration with families, to reconsider the current regimen and to introduce additional ASMs in an effort to improve outcomes. Before introducing an additional ASM into an existing regimen, several elements must be weighed carefully, including target dosing, expected efficacy, potential contraindications, drug–drug interactions, pharmacokinetic characteristics, safety profile, management of adverse events, impact on comorbidities, cost and reimbursement considerations, and clinical or laboratory monitoring. 7 , 14 At the same time, the evolving needs of patients and their families over the course of the disease add another layer of complexity, 5 , 6 underscoring the need for a comprehensive and holistic approach for DS therapeutic management. To address this need, a European structured consensus project was conducted to develop practical guidance on optimizing treatment combinations for patients with DS. 15 In this work, nearly 90% of the statements reached consensus among DS experts, particularly on key aspects of management such as caregiver empowerment, initiation and titration parameters for key ASMs, drug–drug interaction management, and treatment monitoring, providing a solid foundation for practical guidance in clinical decision‐making. As country‐specific practices, drug indications, and approval timelines differ between the US and Europe, 7 , 8 , 16 , 17 , 18 the present work aimed to apply this European consensus approach to the US context, in order to define practical, shared principles guiding US clinicians in managing multidrug regimens. Given the early onset of seizures, the importance of initiating DS‐specific treatments as early as possible, and the fact that STP is currently the only DS‐specific antiseizure medication authorized for use at very young age (from 6 months in the United States), a particular focus was placed on regimens involving STP. MATERIALS AND METHODS This study was conducted between July and October 2025 among North American neurologists with expertise in DS and followed a modified Delphi methodology (Figure 1). The Delphi method is a structured consensus approach that gathers opinions from expert panelists to achieve agreement on specific topics. 19 Widely used in many therapeutic fields, including neurology and epilepsy, 6 , 20 , 21 , 22 this method allows experts to provide individual and anonymous responses, rating their agreement with different statements to reach a consensus on a defined subject. Overview of the methodology used in the consensus work. Steering committee and statements refinement The Steering Committee (SC) consisted of two US clinicians selected for their recognized expertise in DS, DEE and drug–drug interaction management. Both clinicians are actively involved in international expert boards, patient advocacy groups, and were also members of the European consensus Steering Committee. To ensure relevance with US clinical context, the statements from the European consensus were reviewed, analyzed, and refined by the SC, resulting in a total of 35 statements submitted for voting by a larger panel of US experts. These statements covered key aspects of polytherapy management in patients with DS and were organized into six sections: (i) General principles; (ii) Guiding physicians to empower patients and their caregivers; (iii) STP as an add‐on to specific and nonspecific Dravet ASMs; (iv) FFA within a regimen containing STP; (v) CBD within a regimen containing STP; and (vi) Patient follow‐up during treatment initiation. A single voting round—rather than the two typically used in Delphi methodology—was implemented in this study. This approach is consistent with published methodological guidance indicating that a one‐round process is appropriate when items are derived from previous studies or prior consensus efforts. 23 , 24 Voting expert panel selection The voting panel was identified using a multistep selection process. An initial pool of US‐based neurologists with experience in epilepsy care was established using publicly available professional databases and national clinical networks. From this pool, potential participants were further identified based on multiple criteria, including documented experience in the clinical management of DS, regular prescription of DS‐specific approved antiseizure medications, participation in DS‐focused scientific meetings, involvement in DS‐related research or professional networks, and engagement with patient advocacy or specialist organizations as well as broad geographical representation across the United States. Ultimately, 51 clinicians from the US and 1 clinician from Canada (Toronto) were invited to participate as a panelist. All were required to complete a standardized survey prior to voting, documenting their clinical experience, patient volume, and involvement in DS‐related care, to ensure an appropriate level of expertise among respondents. Final selection of invitees was reviewed and validated by the Steering Committee to ensure appropriate clinical expertise. The SC and voting panel maintained anonymity throughout the process, with SC members not taking part in the voting, in line with current methodological recommendations. 25 Voting process The 52 experts were sent a personalized electronic invitation to an online survey platform by an independent third party, where they were asked to rate the 35 recommendation statements using a nine‐point Likert scale (1 = strongly disagree, 9 = strongly agree). Consensus thresholds were defined as follows: 25 A “strong consensus” was reached if more than 75% of scores were ≥7 and the median score was ≥8.A “good consensus” was considered if only one of these two criteria was met.“No consensus” was determined if neither criterion was met. A “strong consensus” was reached if more than 75% of scores were ≥7 and the median score was ≥8. A “strong consensus” was reached if more than 75% of scores were ≥7 and the median score was ≥8. A “good consensus” was considered if only one of these two criteria was met. A “good consensus” was considered if only one of these two criteria was met. “No consensus” was determined if neither criterion was met. “No consensus” was determined if neither criterion was met. A free‐comment section for each statement allowed them to explain their choices. A “no opinion” option was available; responses with this selection were removed from statistical analysis. The platform remained open for two months, and nonresponding experts were sent 3 reminder emails. Following closure of the voting platform on September 22, 2025, a final meeting with the SC members was convened in October 2025 to review, discuss, and summarize the results. RESULTS Responding expert physicians’ profile Of the 52 experts invited, 26 took part in the voting process (50% response rate) (Figure 2). The cohort demonstrated a high level of experience, with a median of 15 [8–35] years since first managing a patient with DS and a median of 16.5 [5–125] DS patients currently followed. Over the past five years, 23/26 experts (89%) had been involved in at least one of the following: participation in a DS clinical trial (81%), participation in a DS research project (65%), presentation at a DS congress (54%), authorship of a scientific publication on DS (50%), or participation as a trainer in DS courses/workshop (35%). Characteristics of the voting panel. Results of the voting process Overall, 23 of the 35 statements (66%) reached strong consensus, 6 (17%) achieved good consensus, and 6 (17%) did not achieve consensus. The distribution of votes, including the medians, and the results for each section are presented in Table 1. TABLE 1Final voting results.Statements%1–2‐3 (n)%4–5‐6 (n)%7–8‐9 (n)MedianConsensusGeneral principles1Due to the high risk of prolonged seizures in individuals with Dravet Syndrome, every patient should be prescribed a rescue medication and be provided with a clearly defined seizure action plan. 0% (0) 0% (0) 100% (26)9Strong2Before starting a new ASM, it is advisable to first optimize the dosage of the current medications (regimen), with careful consideration of both efficacy and tolerability. 0% (0) 4% (1) 96% (25)9Strong3Following the initiation of a new therapy and subsequent adjustments to the current ASM regimen, fluctuations in seizure frequency and/or severity may be observed. As these transient fluctuations may not be predictive of long‐term response, an adequate trial period should be allowed to assess the new treatment's efficacy and tolerability before making further modifications. 4% (1) 0% (0) 96% (25)8.5Strong4Sodium channel–blocking ASMs should be avoided for daily use following a diagnosis of Dravet syndrome. 0% (0) 8% (2) 92% (24)9Strong5When introducing STP or CBD into an ASM regimen, potential adverse effects are typically identifiable through clinical observation. Routine monitoring of plasma levels is not required for optimizing therapeutic efficacy and tolerability; however, monitoring levels of concomitant ASMs may be considered to better understand potential drug–drug interactions. 3% (1) 27% (7) 70% (18)8Good6ASM changes may partly impact comorbidities, however the underlying causes of comorbidities are multifactorial. Comorbidities require ongoing evaluation and targeted intervention. 0% (0) 0% (0) 100% (24)9StrongGuiding physician to empower parents or caregiver7Physicians should engage parents or caregivers in treatment decisions, ensuring a discussion of the potential benefits and drawbacks of the available options, such as ASMs, dietary therapies, and neuromodulation. 0% (0) 0% (0) 100% (26)9Strong8Physicians should discuss with parents or caregivers about referral and potential inclusion in clinical trials. 0% (0) 0% (0) 100% (26)9Strong9When initiating a new treatment, physicians should provide parents or caregivers with clear expectations about expected efficacy and potential side effects. 0% (0) 0% (0) 100% (26)9Strong10Physicians should provide parents or caregivers written instructions on medication titration and tapering, along with guidance on monitoring seizures, identifying adverse effects, and determining when and how to seek medical advice. 0% (0) 0% (0) 100% (26)9StrongSTP as an add‐on to other ASMs11Before adding STP to a regimen that includes other ASMs, the benefit of each existing ASM should be discussed, to later guide a potential taper of the ASM that is not providing meaningful seizure reduction. 0% (0) 4% (1) 96% (25)9Strong12When introducing STP into an ASM regimen, including CLB and/or VPA, a notable reduction in seizure frequency and duration is typically expected, along with reduction or cessation of prolonged convulsive seizures and status epilepticus. Seizure reduction could be seen early; but may require up to 4–6 weeks, at optimal dosing, before significant seizure benefits are observed. 4% (1) 11.5% (3) 84.5% (22)8Strong13When introducing STP into any ASM regimen, starting at 15–20 mg/kg/day is advised, followed by a gradual increase over 2–4 weeks to the initial target dose, adjusted according to seizure frequency, effectiveness, and tolerability. 0% (0) 23% (6) 77% (20)7.5Good14When adding STP to any base regimen of ASM, the weight and age of the patient must be considered: children younger than 5 years old usually require higher targeted dose (40–50 mg/kg/day), whereas adolescents require lower targeted dose (20–30 mg/kg/day). 0% (0) 28% (7) 72% (18)7No15When adding STP to a regimen that includes CLB and/or VPA, an early dose reduction of CLB and/or VPA should be considered to help minimize adverse effects, which are likely due to pharmacodynamic or pharmacokinetic effects. 0% (0) 11.5% (3) 88.5% (23)8Strong16When introducing STP, potential drug interactions with CLB should be considered: If CLB is already part of the regimen, adjusting its dosage to a maximum of 0.5 mg/kg/day may improve tolerabilityIn cases where adverse effects such as sedation, somnolence, or ataxia occur, tolerability can be improved by reducing CLB by 25%. 0% (0) 20% (5) 80% (20)8Strong17When introducing STP, potential drug interactions with VPA should be considered: If VPA is already part of the regimen, adjusting its dosage to a maximum of 30 mg/kg/day may improve tolerability.In cases where adverse effects such as sedation, decreased appetite, weight loss, or thrombocytopenia occur, tolerability can be improved by reducing VPA by 30%. 0% (0) 20% (5) 80% (20)7Good18When introducing STP, potential drug interactions with FFA should be considered. FFA must be adjusted to a maximum of 0.4 mg/kg/day, with a total daily dose not exceeding 17 mg. 0% (0) 4% (1) 96% (24)9Strong19When introducing STP, potential drug interactions with CBD should be considered: No specific dose adjustments are necessary for either CBD or STP.The addition of STP is not anticipated to further influence the pharmacokinetics of other concurrent medications, such as CLB. Therefore, no additional dose modification of CLB is required. Nonetheless, careful clinical monitoring is advised. 19% (5) 19% (5) 62% (15)7No20When introducing STP, no specific dose adjustment is necessary for TPM or LEV. 4% (1) 12.5% (3) 83.5% (20)8StrongFFA in a regimen containing STP21When introducing FFA into an ASM regimen that includes STP, a notable reduction in seizure frequency is typically expected within 6–8 weeks after reaching the target dose. 4% (1) 17.5% (4) 78.5% (18)7Good22When introducing FFA into an ASM regimen that includes STP, an initial dose of 0.1–0.2 mg/kg/day is recommended. Gradual titration by 0.1 mg/kg/day every 1–2 weeks, based on treatment response and tolerability, should be implemented, with a maximum target dose of 0.4 mg/kg/day, not exceeding 17 mg/day. 0% (0) 4% (1) 96% (24)9Strong23Before initiating FFA, an echocardiography must be conducted to ensure there are no signs of aortic or mitral valvular heart disease or pulmonary arterial hypertension. Follow‐up echocardiograms must be performed every six months. Additionally, a final echocardiogram must be conducted 3–6 months after the last dose of FFA. 0% (0) 4% (1) 96% (25)9Strong24When introducing FFA into an ASM regimen that includes STP, CLB and/or VPA, maintaining STP should be considered if it has resulted in clinically meaningful reduction in seizure frequency and/or status epilepticus. 4% (1) 15% (4) 81% (21)9Strong25When introducing FFA into an ASM regimen that includes STP, CLB and/or VPA, common adverse effects such as decreased appetite, fatigue, and somnolence may occur. These effects are often temporary, but if they persist, adjusting to a lower FFA dose could be considered. 0% (0) 27% (7) 73% (19)7NoCBD in a regimen containing STP26When incorporating CBD into an ASM regimen that includes STP, a moderate decrease in overall seizure frequency is typically expected. 0% (0) 44% (11) 56% (14)7No27When introducing CBD into an ASM regimen that includes STP, initiation at 2.5 mg/kg/day is recommended, with 2 mg/kg/day weekly increases to an initial target dose of 10–12 mg/kg/day over 3–4 weeks. Treatment response should then be assessed, with further increases of 2.5 mg/kg/day every 1–2 weeks if seizures persist, up to a maximum dose of 20 mg/kg/day if well tolerated. 11.5% (3) 27% (7) 61.5% (16)7No28Since STP already interacts pharmacokinetically with CLB, no additional dose reduction of CLB is required when introducing CBD to a patient already receiving both STP and CLB unless further adverse events present. 4% (1) 54% (14) 42% (11)6No29When introducing CBD into an ASM regimen that includes STP, CBD's effectiveness should be evaluated within three months. 0% (0) 24% (6) 76% (19)7Good30When introducing CBD into an ASM regimen that includes STP, CLB and/or VPA, maintaining STP should be considered if it has resulted in clinically meaningful seizure improvement and/or a reduction in status epilepticus. 4% (1) 15% (4) 81% (21)8.5Strong31When introducing CBD into an ASM regimen that includes VPA, Liver Function Tests should be conducted periodically due to the potential risk of transaminitis associated with the interaction between CBD and VPA. 0% (0) 8% (2) 92% (24)9Strong32When introducing CBD into an ASM regimen that includes STP, CLB and/or VPA, common adverse effects such as sedation, somnolence, fatigue, ataxia, diarrhea, nausea, and anorexia may occur. These effects are often temporary, but if present, adjusting to a lower target CBD dose and implementing a slower titration schedule could be considered. 0% (0) 11.5% (3) 88.5% (23)8StrongPatient follow‐up during treatment initiation33After adding a new treatment, an initial follow‐up via a nurse and/or physician contact, telephone, or secure email within 1–2 weeks to assess titration and tolerability of the new ASM regimen should be considered. 12% (3) 19% (5) 69% (18)8Good34A follow‐up contact should be scheduled 1 to 3 months after treatment initiation to evaluate the treatment's safety and effectiveness. 4% (1) 7.5% (2) 88.5% (23)9Strong35When STP is added to CLB and VPA, blood counts and liver function should be assessed prior to starting treatment with STP and should be checked every 6 months unless otherwise clinically indicated. 8% (2) 16% (4) 76% (19)8Strong Note: For each statement, a total number of voters different from 26 indicates that the panel used the “no opinion” option. Final voting results. 0% (0) 0% (0) 0% (0) 4% (1) 4% (1) 0% (0) 0% (0) 8% (2) 3% (1) 27% (7) 0% (0) 0% (0) 0% (0) 0% (0) 0% (0) 0% (0) 0% (0) 0% (0) 0% (0) 0% (0) 0% (0) 4% (1) 4% (1) 11.5% (3) 0% (0) 23% (6) 0% (0) 28% (7) 0% (0) 11.5% (3) If CLB is already part of the regimen, adjusting its dosage to a maximum of 0.5 mg/kg/day may improve tolerability If CLB is already part of the regimen, adjusting its dosage to a maximum of 0.5 mg/kg/day may improve tolerability In cases where adverse effects such as sedation, somnolence, or ataxia occur, tolerability can be improved by reducing CLB by 25%. In cases where adverse effects such as sedation, somnolence, or ataxia occur, tolerability can be improved by reducing CLB by 25%. 0% (0) 20% (5) If VPA is already part of the regimen, adjusting its dosage to a maximum of 30 mg/kg/day may improve tolerability. If VPA is already part of the regimen, adjusting its dosage to a maximum of 30 mg/kg/day may improve tolerability. In cases where adverse effects such as sedation, decreased appetite, weight loss, or thrombocytopenia occur, tolerability can be improved by reducing VPA by 30%. In cases where adverse effects such as sedation, decreased appetite, weight loss, or thrombocytopenia occur, tolerability can be improved by reducing VPA by 30%. 0% (0) 20% (5) 0% (0) 4% (1) No specific dose adjustments are necessary for either CBD or STP. No specific dose adjustments are necessary for either CBD or STP. The addition of STP is not anticipated to further influence the pharmacokinetics of other concurrent medications, such as CLB. Therefore, no additional dose modification of CLB is required. Nonetheless, careful clinical monitoring is advised. The addition of STP is not anticipated to further influence the pharmacokinetics of other concurrent medications, such as CLB. Therefore, no additional dose modification of CLB is required. Nonetheless, careful clinical monitoring is advised. 19% (5) 19% (5) 4% (1) 12.5% (3) 4% (1) 17.5% (4) 0% (0) 4% (1) 0% (0) 4% (1) 4% (1) 15% (4) 0% (0) 27% (7) 0% (0) 44% (11) 11.5% (3) 27% (7) 4% (1) 54% (14) 0% (0) 24% (6) 4% (1) 15% (4) 0% (0) 8% (2) 0% (0) 11.5% (3) 12% (3) 19% (5) 4% (1) 7.5% (2) 8% (2) 16% (4) Note: For each statement, a total number of voters different from 26 indicates that the panel used the “no opinion” option. General principles (6 statements) 5 statements reached strong consensus, and one reached good consensus. US voters unanimously agreed on the importance of providing all individuals with DS a rescue medication and a clearly defined seizure action plan (statement #1) as well as optimizing the existing ASM regimen—balancing efficacy and tolerability—before initiating any new therapy (#2). They also agreed that transient seizure fluctuations may occur after treatment changes and that an adequate trial period is required to assess efficacy and tolerability (#3). There was strong agreement that sodium channel–blocking ASMs should be avoided in confirmed DS for daily use (#4), and that comorbidities, although multifactorial, require ongoing evaluation and targeted care (#6). One statement achieved good consensus: routine ASM plasma monitoring, when adding STP or CBD, was not considered necessary to optimize therapeutic efficacy and tolerability, although some experts noted that measuring concomitant drug levels may help clarify drug–drug interactions and guide dose adjustments (#5). Guiding physician to empower patients (4 statements) All 4 statements reached strong consensus. Experts agreed that physicians should actively involve caregivers in treatment decisions, while emphasizing that clinicians must retain full therapeutic responsibility and avoid allowing families to determine treatment choices on their own (#7). Strong consensus was also achieved on discussing referral or potential inclusion in clinical trials (#8), setting clear expectations regarding efficacy and adverse effects when initiating new treatments (#9), and providing written instructions for titration, tapering, monitoring, and guidance on when to seek medical advice (#10). STP as an add‐on to specific and nonspecific Dravet ASMs (10 statements) Among the 10 statements, 6 reached strong consensus, two reached good consensus, and two did not reach consensus. There was strong agreement on reviewing the benefit of each existing ASM before adding STP, to discontinue agents with no meaningful efficacy and limit unnecessary polytherapy (#11). In addition, experts agreed on the expected reduction in seizure frequency and duration once the optimal STP dose is reached (#12). Experts also agreed that an early dose reduction of CLB and/or VPA before adding STP may improve tolerability (#15). Strong consensus was also reached regarding specific ASM adjustments when introducing STP, including limiting CLB to ≤0.5 mg/kg/day and reducing the dose by 25% in case of adverse effects (#16), adjusting FFA to a maximum of 0.4 mg/kg/day (#18), and the absence of required dose adjustments for TPM or LEV (#20). 2 statements achieved good consensus. The first concerned initial STP titration (starting at 15–20 mg/kg/day and titrating over 2–4 weeks), although some experts indicated they prefer initiating STP at lower doses (around 10 mg/kg/day) (#13). The second related to VPA management when adding STP (target dose ≤30 mg/kg/day), with reductions of ~30% if adverse events occur, with several experts noting that they would first consider the clinical response or VPA plasma levels before deciding on dose reduction (#17). Finally, 2 statements did not reach consensus. The first concerned age‐ and weight‐dependent STP target doses (#14), which remained close to consensus (72% of votes ≥ 7; median 7). The second statement concerned whether CLB dose adjustment is required when introducing STP into a regimen already containing CBD and CLB. Although the statement proposed that no additional CLB adjustment was needed because STP is not expected to further influence CLB pharmacokinetics, some experts did not agree, with several indicating that the addition of STP in such a regimen may further increase CLB levels (#19). FFA in a regimen containing STP (5 statements) 3 statements reached strong consensus, one achieved good consensus, while one did not reach consensus. Experts strongly agreed on the need for baseline and periodic echocardiography when introducing FFA to a regimen to rule out valvular heart disease and pulmonary arterial hypertension (#23). They also agreed on FFA titration when combined with STP—starting at 0.1–0.2 mg/kg/day and increasing by 0.1 mg/kg/day every 1–2 weeks to a maximum of 0.4 mg/kg/day (not exceeding 17 mg/day) (#22)—and on maintaining STP in the regimen when it has demonstrated clinically meaningful benefit before FFA initiation (#24). Expectations for seizure improvement within 6–8 weeks of achieving the target FFA dose reached good consensus, with some experts stating that the benefit could be seen earlier (#21). One statement did not reach consensus regarding the potential need for a lower FFA dose in case of adverse events, with experts noting that another co‐medication—such as CLB—could instead be reduced to help limit adverse effects (#25). CBD in a regimen containing STP (7 statements) Among the 7 statements, 3 achieved strong consensus, one achieved good consensus, and three did not reach consensus. There was strong agreement on the need to maintain STP when introducing CBD if it has previously provided seizure improvement (#30), monitor liver function when CBD is used with VPA (#31), and consider slower CBD titration or lower target dose in case of adverse effects (#32). Good consensus was reached on evaluating CBD efficacy within three months after initiation (#29). 3 statements did not reach consensus regarding: The expected moderate seizure reduction following CBD introduction (#26), with experts stating that the variability of efficacy among patients is too high to support a general statement predicting a moderate reduction in seizure frequency.The recommended initial CBD titration with an initial dose of 2.5 mg/kg/day with 2 mg/kg/day weekly increases to an initial target dose of 10–12 mg/kg/day over 3–4 weeks, with some experts initiating CBD at lower doses and others aiming for higher target doses than those proposed. (#27)Whether additional CLB adjustment is needed when adding CBD to a regimen already containing STP and CLB (#28). Here, several experts indicated that although no further pharmacokinetic interaction between CBD and CLB is expected in theory, in practice adding CBD in such a regimen frequently increases adverse effects and may therefore warrant CLB dose reduction. The expected moderate seizure reduction following CBD introduction (#26), with experts stating that the variability of efficacy among patients is too high to support a general statement predicting a moderate reduction in seizure frequency. The expected moderate seizure reduction following CBD introduction (#26), with experts stating that the variability of efficacy among patients is too high to support a general statement predicting a moderate reduction in seizure frequency. The recommended initial CBD titration with an initial dose of 2.5 mg/kg/day with 2 mg/kg/day weekly increases to an initial target dose of 10–12 mg/kg/day over 3–4 weeks, with some experts initiating CBD at lower doses and others aiming for higher target doses than those proposed. (#27) The recommended initial CBD titration with an initial dose of 2.5 mg/kg/day with 2 mg/kg/day weekly increases to an initial target dose of 10–12 mg/kg/day over 3–4 weeks, with some experts initiating CBD at lower doses and others aiming for higher target doses than those proposed. (#27) Whether additional CLB adjustment is needed when adding CBD to a regimen already containing STP and CLB (#28). Here, several experts indicated that although no further pharmacokinetic interaction between CBD and CLB is expected in theory, in practice adding CBD in such a regimen frequently increases adverse effects and may therefore warrant CLB dose reduction. Whether additional CLB adjustment is needed when adding CBD to a regimen already containing STP and CLB (#28). Here, several experts indicated that although no further pharmacokinetic interaction between CBD and CLB is expected in theory, in practice adding CBD in such a regimen frequently increases adverse effects and may therefore warrant CLB dose reduction. Patient follow‐up during treatment initiation (3 statements) In this section, 2 statements reached strong consensus and one reached good consensus. Experts supported with good consensus early follow‐up within 1–2 weeks after treatment initiation (#33) and with strong consensus another structured assessment within 1–3 months (#34). They also agreed on the need for baseline and periodic monitoring—blood counts and liver function testing—when STP is combined with CLB and VPA, with reassessment every 6 months unless otherwise indicated (#35). DISCUSSION While DS requires individualized treatment approaches, the large number of therapeutic options and the need to balance efficacy, safety, drug interactions, and tolerability 14 highlight the need for structured, evidence‐based, polytherapy guidance. A recent study developed practical guidance to support clinical decision‐making and improve communication with families regarding the goals and implications of combination therapy in Dravet syndrome (DS). 15 However, this work primarily reflected European clinical practice, as approximately 90% of participants were based in Europe, with only a few from other regions and none from the United States, despite the country having a large population of DS patients and one of the largest populations of pediatric neurologists worldwide. 17 , 18 In addition, differences exist between Europe and the U.S. in terms of ASM approval timelines (e.g., STP was approved in 2007 in Europe and in 2018 in the United States) and indications, with CLB required in combination with STP in the United States, whereas both VPA and CLB are required in Europe. 9 , 10 Furthermore, recent retrospective studies have identified distinct therapeutic patterns in the United States, with DS‐specific ASMs such as STP and FFA being underutilized compared with agents typically considered third‐line or beyond, such as levetiracetam or diazepam. 16 In this context, the present study aimed to develop a US‐focused consensus to guide physicians in the management of treatment combinations in DS, taking into account US‐specific practices. One essential aspect of DS management is the need for strong communication with parents and caregivers. 26 In this regard, all statements from Section 2 (“Guiding physicians to empower parents or caregivers”) and Section 6 (“Patient follow‐up during treatment initiation”) have reached a strong consensus among the US clinician voters. This high level of agreement reflects a strong convergence among experts on these complex but essential dimensions of care, 27 in line with findings from a recent study conducted by Brunklaus et al. 20 Within the complex therapeutic landscape of DS, clinicians have access to three ASMs (STP, FFA and CBD) specifically approved for the treatment of DS‐associated seizures, supported by robust evidence demonstrating efficacy and a well‐characterized safety profile. 10 , 11 , 12 These data enable clinicians to engage in informed, evidence‐based discussions with families regarding expected seizure reduction and the long‐term durability of treatment response. Nonetheless, as already stated, a recent analyses on utilization data has shown that the use of STP and FFA remains limited in the United States, 16 which contrasts with several previously published recommendations that strongly advocate for the early use of these DS‐specific therapies in the treatment pathway. 7 , 28 , 29 , 30 The use of STP and FFA in the United States also appears to be lower than ASMs typically considered third‐line or beyond, such as levetiracetam, that remain largely used despite lack of evidence in this population. 7 , 8 , 16 This was recently confirmed by the retrospective STIRUS study, which demonstrated in a contemporary US cohort that although DS is now diagnosed at earlier ages compared to 2013, the median age at STP initiation has remained stable at 6.9 years. 31 Notably, many patients received third‐line therapies or even contraindicated medications before STP introduction. 31 One potential explanation for STP underuse may relate to its later FDA approval (2018 in the United States vs. 2007 in Europe), which may be associated with lower clinician familiarity, thereby limiting its utilization in clinical practice. 16 In addition, the pivotal randomized, placebo‐controlled clinical trial showing a significant reduction in seizures was published in 2000—almost 18 years before FDA approval— 9 which may limit its perceived relevance in current clinical decision‐making despite consistent support for the efficacy and safety of STP from more recent prospective and retrospective real‐world studies worldwide. 10 , 31 , 32 , 33 , 34 , 35 For FFA, despite a reassuring cardiac safety profile to date, there may be heightened safety concerns for both clinicians and families due to prior history of the drug. 16 In the present work, experts reached strong consensus not only on the expected efficacy of STP and FFA, but also on two practical principles of polytherapy management: withdrawing an ASM that has proven ineffective after STP is introduced, and maintaining STP in the regimen when adding a new ASM if it has already demonstrated sustained clinical benefit. These findings further underscore the importance of clear communication around prioritizing evidence‐based, high‐efficacy therapies while discontinuing agents with limited benefit or limited supporting evidence. 6 , 30 , 31 , 32 , 33 , 34 , 35 , 36 Another key area of consensus concerned the multiple parameters that must be considered when introducing a new ASM—such as efficacy, potential drug–drug interactions, pharmacokinetic properties, and adverse‐effect management—which collectively contribute to the high complexity of DS treatment for clinicians. In this study, US experts reached consensus on several practical aspects of initiating FFA and STP, including recommended starting doses, titration schedules, and target doses. These points are consistent with previously published recommendations, official product information, and the strong consensus also obtained in the European consensus on these key aspect of DS management. 7 , 10 , 30 , 36 , 37 , 38 For STP, the only statement that did not achieve consensus in this section concerned the recommendation of lower target doses in adolescents compared with younger children—although the median score (7/9) suggested near‐consensus. This recommendation is supported by real‐world evidence reporting the use of lower mg/kg doses in adolescents. 29 , 36 , 39 In addition, findings from Peigné et al. showed that apparent clearance and volume of distribution are weight‐dependent, with a marked increase in exposure as body weight increases, 40 which can contribute to increased sensitivity to STP in older patients. Here, the lack of consensus may reflect limited experience with STP use in adolescents among some US respondents, as suggested by voters comments, and may also be related to dosing recommendations in the STP prescribing information, which do not explicitly address age‐ or weight‐related pharmacokinetic variability. 37 This result highlights the need for increased awareness and dissemination of existing data to optimize treatment strategies in specific patient subgroups. The main areas of disagreement in this study concerned the management of CBD and its interplay within regimens containing STP. Notably, the statement regarding its expected efficacy did not reach consensus (“When incorporating CBD into an ASM regimen that includes STP, a moderate decrease in overall seizure frequency is typically expected”, statement #26). The choice of wording in the statement—“moderate efficacy” rather than “significant efficacy”—may have influenced responses; however, comments from voting experts mainly reflected the high variability in clinical response observed in patients treated with CBD. This aligns with clinical trial data showing lower seizure reduction with CBD compared with the two other DS‐specific ASMs, and its frequent positioning as a third‐line option in recommendations. 6 , 7 , 30 , 41 Interestingly, unlike the strong agreement obtained for STP and FFA titration plans, the statement regarding CBD initiation and titration strategy did not reach consensus. Experts disagreed on the recommended dosing strategy of CBD, with some advocating for lower starting doses and others for higher target doses than those proposed (initiation at 2.5 mg/kg/day with titration toward 20 mg/kg/day). Despite the lack of consensus on this statement, retrospective data indicate that CBD is currently the most prescribed DS‐specific ASM in the United States. 6 , 16 , 31 One potential explanation is its early visibility, which may have initially increased awareness among parents and caregivers and led to frequent treatment requests, as highlighted in an international consensus led by Wirrell et al. in 2022. 6 Finally, another area of disagreement concerned the pharmacokinetic interplay among CBD, CLB, and STP: no consensus was reached on whether additional CLB dose reduction is necessary when CBD is added to a regimen already containing STP and CLB. Although a study by Devinsky et al. suggested that maintaining the CLB dose may be acceptable in this situation, 42 the sample size was limited, and several US voting experts reported in practice the need to lower CLB in this context to improve tolerability. Overall, the absence of consensus reinforces the need for further experimental and pharmacokinetic studies to clarify these complex ASM interactions and provide clinicians with clear, evidence‐based dosing guidance. As with all consensus methodologies, this study has several limitations. First, although the Delphi process is structured, it remains constrained by the criteria used to define consensus. In this study, these criteria were particularly stringent, more so than in other published work in pediatric neurology. 21 , 22 Second, the composition of the voting panel may not fully reflect the diversity of US clinicians involved in DS care. 41 In addition, certain statements were complex, at times combining multiple subelements within a single item, which can make agreement more difficult to achieve. Third, another limitation concerns the use of a single‐round approach rather than the two‐round process typically employed in Delphi studies. Although this choice was methodologically justified and supported by previously published work for consensus‐extension designs, 23 , 24 a second voting round would likely have allowed further re‐evaluation and refinement of expert opinions. Finally, this work primarily focused on providing guidance for the management of polytherapy in Dravet syndrome, given the wide range of available medications and the complexity of drug–drug interactions. However, certain important aspects of DS management were not addressed, including nonseizure‐related factors and outcomes, as well as the optimal sequencing of therapeutic options. A dedicated consensus addressing these areas would be valuable to achieve a more comprehensive and exhaustive set of practical guidelines covering all aspects of the complex management of patients with DS. CONCLUSION By integrating published evidence with real‐world clinical experience, this work provides practical, shared principles to guide US clinicians in the management of multidrug regimens, particularly for those less familiar with STP use or DS polytherapy. This US study also confirms the inherent complexity of DS polytherapy and highlights the need for a pragmatic, stepwise approach that reassesses ongoing treatments, defines clear objectives for any added ASM, and maintains a strong therapeutic partnership with caregivers, which is essential for optimal patient care. AUTHOR CONTRIBUTIONS The authors were part of the Steering Committee and equally contributed to this study: defined the final scope of the study, reviewed the literature, and reformulated and voted on statements. They all critically reviewed the manuscript for intellectual content, integrated revisions, and agreed to the publication of the manuscript. CONFLICT OF INTEREST STATEMENT Prof. EW has received consulting fees from Biocodex and Jazz Pharma. She serves on the DSMB for Neurocrine, GRIN pharma, Acadia, and Encoded. Prof. JS has received research funding from Zogenix, UCB, Stoke Therapeutics, Encoded Therapeutics, Xenon Pharmaceuticals, Neurocrine Biosciences, and Takeda. He has served as a consultant for the Epilepsy Study Consortium, Jazz Pharmaceuticals, UCB Pharma, Marinus Pharmaceuticals, BrightMinds, Longboard, and Ceribell. He serves on the DSMB for Neuropace. He also holds restricted stock units from Zynerba. The authors confirm that they have read the Journal’s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines. Supporting information Table S1. List of voters agreeing to be acknowledged in the article (n = 24/26).